^
Association details:
| Biomarker: | FGFR translocation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1329P - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
Published date:
10/16/2023
Excerpt:
According to the first stage results of the two-stage Simon’s design, erdafitinib showed preliminary efficacy in NSCLC with FGFR translocations.
Trial ID:
